Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Fang Huang, … , John D. Minna, Ralph J. DeBerardinis
Fang Huang, … , John D. Minna, Ralph J. DeBerardinis
Published October 20, 2020
Citation Information: J Clin Invest. 2021;131(1):e139929. https://doi.org/10.1172/JCI139929.
View: Text | PDF
Research Article Metabolism Oncology

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer

  • Text
  • PDF
Abstract

MYC stimulates both metabolism and protein synthesis, but how cells coordinate these complementary programs is unknown. Previous work reported that, in a subset of small-cell lung cancer (SCLC) cell lines, MYC activates guanosine triphosphate (GTP) synthesis and results in sensitivity to inhibitors of the GTP synthesis enzyme inosine monophosphate dehydrogenase (IMPDH). Here, we demonstrated that primary MYChi human SCLC tumors also contained abundant guanosine nucleotides. We also found that elevated MYC in SCLCs with acquired chemoresistance rendered these otherwise recalcitrant tumors dependent on IMPDH. Unexpectedly, our data indicated that IMPDH linked the metabolic and protein synthesis outputs of oncogenic MYC. Coexpression analysis placed IMPDH within the MYC-driven ribosome program, and GTP depletion prevented RNA polymerase I (Pol I) from localizing to ribosomal DNA. Furthermore, the GTPases GPN1 and GPN3 were upregulated by MYC and directed Pol I to ribosomal DNA. Constitutively GTP-bound GPN1/3 mutants mitigated the effect of GTP depletion on Pol I, protecting chemoresistant SCLC cells from IMPDH inhibition. GTP therefore functioned as a metabolic gate tethering MYC-dependent ribosome biogenesis to nucleotide sufficiency through GPN1 and GPN3. IMPDH dependence is a targetable vulnerability in chemoresistant MYChi SCLC.

Authors

Fang Huang, Kenneth E. Huffman, Zixi Wang, Xun Wang, Kailong Li, Feng Cai, Chendong Yang, Ling Cai, Terry S. Shih, Lauren G. Zacharias, Andrew Chung, Qian Yang, Milind D. Chalishazar, Abbie S. Ireland, C. Allison Stewart, Kasey Cargill, Luc Girard, Yi Liu, Min Ni, Jian Xu, Xudong Wu, Hao Zhu, Benjamin Drapkin, Lauren A. Byers, Trudy G. Oliver, Adi F. Gazdar, John D. Minna, Ralph J. DeBerardinis

×

Figure 1

Distinct metabolomic subsets of primary human SCLC.

Options: View larger image (or click on image) Download as PowerPoint
Distinct metabolomic subsets of primary human SCLC.
(A and B) Protein ab...
(A and B) Protein abundance of ASCL1 and MYC in tumors from treatment-naive SCLC patients. Tumors labeled gray in B were excluded from further study owing to inadequate metabolite content. (C) Principal component analysis of metabolomics in tumors from A. Individual data points are displayed for 3 fragments from each tumor. (D) Metabolites discriminating between MYChi and MYClo tumors. These metabolites have variable importance in the projection (VIP) scores over 1.0, indicating statistically significant differences between the groups. The bar indicates whether each metabolite is more (red) or less abundant (green) in each group. (E) Relative abundance of purines in MYChi and MYClo tumors. Individual data points are shown with mean and SD for 3 fragments from each tumor. **P < 0.01, ***P < 0.001, ****P < 0.0001. (F) Ki67 values from 33 tumors. Individual data points are shown with mean and SD. Statistical significance was assessed using a 2-tailed Student’s t test (E). Metabolomics was performed once. All other experiments were repeated twice or more.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts